-3.21%
11.12%
6.38%
34.51%
61.04%
302.60%
464.23%
AI Spotlight on CPRX
Company Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies.
It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.The company was formerly known as Catalyst Pharmaceutical Partners, Inc.and changed its name to Catalyst Pharmaceuticals, Inc.
in May 2015.Catalyst Pharmaceuticals, Inc.was founded in 2002 and is based in Coral Gables, Florida.
Market Data
| Last Price | 23.19 |
| Change Percentage | -3.21% |
| Open | 24.16 |
| Previous Close | 23.96 |
| Market Cap ( Millions) | 2766 |
| Volume | 918257 |
| Year High | 24.64 |
| Year Low | 13.12 |
| M A 50 | 21.82 |
| M A 200 | 19.01 |
Financial Ratios
| FCF Yield | 6.80% |
| Dividend Yield | 0.00% |
| ROE | 25.74% |
| Debt / Equity | 0.50% |
| Net Debt / EBIDTA | -228.02% |
| Price To Book | 4.17 |
| Price Earnings Ratio | 19.31 |
| Price To FCF | 14.71 |
| Price To sales | 6.01 |
| EV / EBITDA | 12.08 |
News
- Jan -23 - Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
- Jan -21 - Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan
- Jan -13 - Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE
- Jan -09 - CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
- Jan -09 - Here's Why Momentum in Catalyst (CPRX) Should Keep going
- Jan -09 - Catalyst (CPRX) Soars 16.7%: Is Further Upside Left in the Stock?
- Jan -08 - IBD Tech Leader Catalyst Rockets After Striking A Key Deal With Teva
- Jan -08 - Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals
- Dec -16 - Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Nov -25 - Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
- Nov -19 - Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
- Nov -13 - Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
- Nov -11 - Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
- Nov -08 - 5 Small Drug Stocks to Buy as Trump Gets Re-Elected
- Nov -07 - CPRX Q3 Earnings & Revenues Beat Estimates, '24 View Raised, Stock Up
- Nov -07 - Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2024 Earnings Call Transcript
- Nov -07 - Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?
- Nov -07 - Catalyst (CPRX) Reports Q3 Earnings: What Key Metrics Have to Say
- Nov -06 - Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
- Nov -06 - Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Drug Products
Expected Growth : 10 %
What the company do ?
Catalyst Pharmaceuticals, Inc. develops and commercializes novel therapeutic products, including Firdapse, a treatment for Lambert-Eaton Myasthenic Syndrome.
Why we expect these perspectives ?
Catalyst Pharmaceuticals' 10% growth in drug products is driven by increasing demand for rare disease treatments, expanded product offerings, and strategic partnerships. Growing awareness of rare genetic disorders, such as Lambert-Eaton Myasthenic Syndrome, fuels demand for Catalyst's therapies. Additionally, the company's focus on orphan drug development and commercialization contributes to its growth momentum.
Catalyst Pharmaceuticals, Inc. Products
| Product Range | What is it ? |
|---|---|
| Firdapse | A medication used to treat Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disorder. |
| CPS-1 | A potential treatment for congenital pyruvate kinase deficiency, a rare genetic disorder. |
| CPS-2 | A potential treatment for mitochondrial myopathies, a group of rare genetic disorders. |
Catalyst Pharmaceuticals, Inc.'s Porter Forces
Threat Of Substitutes
Catalyst Pharmaceuticals, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for rare genetic disorders.
Bargaining Power Of Customers
Catalyst Pharmaceuticals, Inc. has a low bargaining power of customers due to the lack of alternative treatments for rare genetic disorders, giving patients limited options.
Bargaining Power Of Suppliers
Catalyst Pharmaceuticals, Inc. has a moderate bargaining power of suppliers due to the dependence on a few key suppliers for raw materials and manufacturing services.
Threat Of New Entrants
Catalyst Pharmaceuticals, Inc. has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including regulatory hurdles and high R&D costs.
Intensity Of Rivalry
Catalyst Pharmaceuticals, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.91% |
| Debt Cost | 3.95% |
| Equity Weight | 99.09% |
| Equity Cost | 8.41% |
| WACC | 8.37% |
| Leverage | 0.92% |
Catalyst Pharmaceuticals, Inc. : Quality Control
Catalyst Pharmaceuticals, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| MDXG | MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts … |
| HRTX | Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic … |
| LQDA | Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of … |
| ARMP | Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's … |
| URGN | UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Catalyst Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
MiMedx
A-Score
1-Year Total Return ->
🥉
Heron Therapeutics
A-Score
1-Year Total Return ->
4
Armata Pharmaceuticals
A-Score
1-Year Total Return ->
5
UroGen Pharma
A-Score
1-Year Total Return ->
6
